Budesonide/formoterol maintenance and reliever therapy: Impact on airway inflammation in asthma

European Respiratory Journal

Volumn 31, Issue 5, 2008, Pages 982-989

  Sears, M R ^a,f   Boulet, L P ^d   Laviolette, M ^d   Fitzgerald, J M ^e   Bai, T R ^e   Kaplan, A ^b   Smiljanic Georgijev, N ^c   Lee, J S M ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b Family Physician Airways Group of Canada   (Canada)

^c ASTRAZENECA   (United Kingdom)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

Asthma; Budesonide formoterol; Control; Exacerbations; Health economics; Inflammation

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; GLUCOCORTICOID; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; BUDESONIDE; ETHANOLAMINE DERIVATIVE; FORMOTEROL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG COST; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FEMALE; HOSPITALIZATION; HUMAN; INHALER; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFLAMMATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 47049106944     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00104007     Document Type: Article

References (16)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. www.ginasthma.com Date last updated: 2007. Date last accessed: December 7, 2006.
2. Lemière C, Bai T, Balter M, et al. Adult Asthma Consensus Guidelines Update 2003. Can Respir J 2004; 11: Suppl. A, 9A-18A.
3. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219-224.
4. Pauwels RA, Löfdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411.
5. Pauwels RA, Sears MR, Campbell M, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22: 787-794.
6. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-136.
7. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26: 819-828.
8. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403-1418.
9. Rabe KF, Pizzichini E, Ställberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129: 246-256.
10. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61: 725-736.
11. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744-753.
12. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158: 924-930.
13. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis 1987; 136: 225-244.
14. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-907.
15. Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996; 154: 308-317.
16. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844.